Introduction {#sec1}
============

During embryonic development, retinoic acid (RA) acts as a morphogen, providing signals that instruct commitment of unspecified precursors toward separate cell fates, thereby helping to mediate tissue patterning and organogenesis ([@bib8; @bib15; @bib29]). As such, RA is also a potent teratogen capable of disturbing developmental processes, causing severe malformations of the fetus. RA is a signaling molecule derived from vitamin A (retinol), regulating cellular proliferation and differentiation, and is produced by cells that express the enzymes retinaldehyde dehydrogenase 1 (RALDH1), RALDH2, or RALDH3. A small molecule, diethylaminobenzaldehyde (DEAB), inhibits the activity of these enzymes and can be used to limit endogenous RA signaling ([@bib19; @bib24; @bib30]). When available, RA enters the nucleus to bind the retinoic acid receptor (RAR) family of nuclear receptors that, in turn, by forming heterodimeric complexes with the retinoid-X-receptor (RXR) family, localize to specific retinoic acid response elements (RAREs) in promoter regions of the genome to drive transcription of RA target genes. Modulation of RA in in vitro models of development provides a useful tool toward understanding commitment into tissues that depend either on high levels of RA, such as the developing ectodermal and endodermal derivatives ([@bib21]) or on low levels of RA such as the posterior patterning of the lateral plate mesoderm (LPM) ([@bib6]). While several model organisms including *Xenopus* (*Xenopus laevis*), zebrafish (*Danio rerio*), and mouse (*Mus musculus*) have been used to study the effects of RA on embryonic development, similar studies have not been possible in the human setting for both technical and ethical reasons. In addition to its role in embryonic development, RA is also known to have strong effects on the hematopoietic lineage. However, the studies on the role of RA in regulating adult hematopoiesis have yielded opposing results. For example, RA signaling inhibition expands hematopoietic progenitors in both the human and murine setting ([@bib4; @bib20]), while other studies report increased maintenance and self-renewal upon adding RA to short- and long-term repopulating hematopoietic stem cells (HSCs) in the murine setting, mediated through activation of the RARγ receptor ([@bib27; @bib28]). These apparent contradictions likely reflect the increasingly complex nature of RA signaling that is emerging in the field, which is why a more contextual understanding might provide a better model to explain these previous findings. Indeed, work analyzing the effects of RA on different subpopulations of adult blood demonstrated that RA has a pleiotropic effect, enhancing the self-renewal of the HSC compartment while accelerating the differentiation of downstream progenitors ([@bib26]). Several groups have created protocols that allow in vitro generation of hematopoietic cells from human pluripotent stem cells ([@bib13; @bib21; @bib35]), with more recent reports demonstrating the generation of definitive hematopoietic cells capable of differentiation into the lymphoid lineage ([@bib14; @bib33]). However, efficient generation of hematopoietic stem and progenitor cells, with functional properties of their in vivo counterparts, remains challenging, possibly due to the current limitations to how accurately the conditions of embryonic blood development can be reproduced in vitro. In this study, using a human pluripotent stem cell differentiation system, we model hematopoietic development and increase the generation efficiency of hematopoietic cells with an HSC-like phenotype by limiting RA signaling during directed pluripotent stem differentiation toward blood. RA signaling inhibition maintains immature progenitors in a less differentiated state and enables efficient commitment toward the hematopoietic lineage during multiple stages of the developmental process. Our results define the role of RA in hematopoietic differentiation and provide evidence that low levels of RA signaling promote hematopoietic development from pluripotent stem cells.

Results {#sec2}
=======

Decreased Retinoic Acid Signaling Increases the Generation of Hematopoietic Progenitors from Human Pluripotent Stem Cells {#sec2.1}
-------------------------------------------------------------------------------------------------------------------------

Using a 16-day embryonic stem cell (ESC)/induced pluripotent stem cell (iPSC) differentiation system based on our previously described protocol ([@bib35]) to model human embryonic development toward the hematopoietic lineage, we assessed the effects of RA signaling on hematopoietic precursor lineage commitment, multilineage differentiation, and proliferation capacities ([Figure 1](#fig1){ref-type="fig"}A). We used established cell-surface markers of hematopoietic progenitors and HSCs and assessed their frequencies in our ESC/iPSC-derived hematopoietic cells ([Figure 1](#fig1){ref-type="fig"}B). The cord blood-based phenotypic markers were as follows: hematopoietic progenitors: CD45^+^CD34^+^, multipotent progenitors (MPPs): CD45^+^CD34^+^CD38^−^CD90^−^CD45RA^+^, and HSCs: CD45^+^CD34^+^CD38^−^CD90^+^CD45RA^−^ ([@bib17]). The early pan hematopoietic marker, CD43 ([@bib34]), was included to ensure that all ESC/iPSC-derived blood cells were identified. Early observations such as accelerated differentiation of OP9 cells to adipocytes, and the presence of beating colonies (indicating the presence of cardiomyocytes) (data not shown) made us consider the possibility of elevated RA signaling in our cultures with a possible impact on final blood generation efficiency. Therefore, RA signaling was evaluated by means of both inhibition using the RA synthesis inhibitor DEAB and by adding RA. The relative proportions of viable hematopoietic cells, hematopoietic progenitors, and HSC-like cells were measured by fluorescence-activated cell sorting (FACS) analysis ([Figure 1](#fig1){ref-type="fig"}B). Viability was assessed by 7-aminoactinomycin D (7AAD) exclusion, and no change in total viability was observed after applying DEAB and RA. RA inhibition by DEAB significantly increased the frequency of HSC-like fraction by 2.3-fold while showing no significant change in the frequency of total hematopoietic cells or the more mature progenitor fraction ([Figure 1](#fig1){ref-type="fig"}C, left panels). This HSC-like cell increase was also seen when using the alternative pluripotent human stem cell lines H1 and HUES33 ([Figures S1](#app2){ref-type="sec"}A and S1B). RA at the highest concentration of 1 μM, reported as a physiological concentration in the developing central nervous system and retina ([@bib29]), resulted in complete abrogation of blood cell production ([Figure 1](#fig1){ref-type="fig"}C, upper right panel). Decreasing doses of RA concentration (0.1 μM and 0.01 μM) restored the presence of hematopoietic progenitors ([Figure 1](#fig1){ref-type="fig"}C). However, the frequency of HSC-like cells remained significantly decreased even at the lowest concentration (0.01 μM) ([Figure 1](#fig1){ref-type="fig"}C, lower right panel). To verify that DEAB and RA were indeed modulating RA signaling in our cultures, we measured the expression level of known RA target gene *RAR-β* and observed a significant decrease in expression with DEAB. At a low concentration of RA, *RAR-β* expression was enhanced ([Figure 1](#fig1){ref-type="fig"}D). In addition, to confirm the role of RA signaling inhibition by DEAB in increasing HSC-like cell frequency, we performed pluripotent stem cell differentiation experiments using the alternative RA signaling inhibitor LG1506, previously described to act as an inverse agonist ([@bib31]), and observed an increase in phenotypic HSCs, similar to DEAB ([Figure 1](#fig1){ref-type="fig"}E). Taken together, these results demonstrate that limiting retinoic acid signaling during pluripotent stem cell differentiation increases the generation of more primitive hematopoietic progenitor cells.

Increased Generation of Hematopoietic Progenitors with Colony-Forming Capacity through Decreased Retinoic Acid Signaling {#sec2.2}
------------------------------------------------------------------------------------------------------------------------

To evaluate the effects of RA signaling on the functionality of blood cells generated from human pluripotent stem cells, we plated 20,000 bulk cells, harvested at day 16, into the colony-forming unit (CFU) assay to measure the output in cells capable of forming hematopoietic colonies when seeded in cytokine containing methylcellulose. Colony types were identified and scored according to their phenotypes ([Figure 2](#fig2){ref-type="fig"}A). Cytospin analysis confirmed the presence of several types of hematopoietic cells including macrophages, monoblasts, myeloblasts, neutrophils, and eosinophils ([Figure 2](#fig2){ref-type="fig"}B). RA inhibition by DEAB during the 16-day differentiation significantly increased the output of CFUs by 2.5-fold as compared to the DMSO control ([Figure 2](#fig2){ref-type="fig"}C, left panel). Compared to the DMSO control, DEAB-treated cultures had a similar distribution of colony types including macrophages, granulocytes, mixed colonies, and erythroid colonies. DEAB-treated cells occasionally gave rise to colonies containing all lineages (GEMM) ([Figure 2](#fig2){ref-type="fig"}C, right panels). In case of differentiating cells treated with RA, we observed a complete lack of CFU potential on using 1 μM RA, confirming the block of hematopoietic cell production ([Figure 2](#fig2){ref-type="fig"}D, left panel). Lower concentrations of RA yielded hematopoietic colonies, with the lowest concentration at 0.01 μM showing a trend (p = 0.17) for an increase in the frequency of colonies. This is likely the result of higher numbers of more mature progenitors (CD34^+^CD38^+^) at the expense of the more immature progenitor fraction (CD34^+^CD38^−^) ([Figure 2](#fig2){ref-type="fig"}E), indicating that RA accelerates the maturation of hematopoietic progenitors. Of note, there were no erythroid colonies at any concentration of RA ([Figure 2](#fig2){ref-type="fig"}D, right panel). Together, these results demonstrate that RA signaling, in a concentration-dependent manner, decreases the generation efficiency of hematopoietic progenitors with colony-forming capacity from human pluripotent stem cells and that reduced RA levels enable a higher generation efficiency of more immature blood cells.

Retinoic Acid Inhibition Enhances the Lymphoid and Myeloid Differentiation Capacity of Hematopoietic Progenitors Generated from Human Pluripotent Stem Cells {#sec2.3}
------------------------------------------------------------------------------------------------------------------------------------------------------------

We set out to assess if the observed increase in the immature progenitor fraction using DEAB, was directly related to the functional improvements seen with the colony assay. We analyzed the differentiation capacity of sorted blood subfractions using a range of different differentiation protocols. First, we sorted equal numbers of hematopoietic progenitor cells (CD45/CD43^+^CD34^+^) that had been generated with or without DEAB and measured their CFU potential. We observed that cells generated with DEAB produced twice the amount of CFUs as compared to the DMSO control and produced a similar number of CFUs when compared to similarly sorted cord blood ([Figure 3](#fig3){ref-type="fig"}A). We then evaluated differentiation capacity of hematopoietic cells toward the lymphoid lineage. We analyzed the lymphoid commitment of hematopoietic progenitors by subculture on either the OP9 or the OP9DL1 stroma. By using OP9 stroma cells for the differentiation toward natural killer (NK) cells, we could evaluate the capacity of the HSC-like (CD34^+^CD38^−^CD90^+^) fraction as compared to the matured fraction (CD34^+^CD38^−^CD90^−^) ([Figures 3](#fig3){ref-type="fig"}B and [S2](#app2){ref-type="sec"}). For reference, sorted cord blood cells were used as positive control. Of note, cord blood cells generally demonstrated \>100-fold higher proliferative capacity compared to their in vitro-generated counterparts across these assays (data not shown). By examining events positive for the markers of NK cells, we observed that the CD90^+^ fraction was superior to the CD90^−^ fraction ([Figure 3](#fig3){ref-type="fig"}B, lower left panel, and [Figure S2](#app2){ref-type="sec"}) indicating that the HSC-like fraction of cells generated from human pluripotent stem cells represents the population with a robust capacity to differentiate toward the lymphoid lineage. For reference, the more mature CD38^+^ hematopoietic fraction (of cells generated in vitro) was evaluated but did not demonstrate any lymphoid or myeloid differentiation capacity (data not shown). NK cluster size from cells generated with or without DEAB showed no significant difference ([Figure 3](#fig3){ref-type="fig"}B, lower left panel); however, given the increase in HSC-like cells ([Figure 1](#fig1){ref-type="fig"}C), the total increase in NK generation from pluripotent stem cells was estimated to be 3-fold using DEAB. We then wanted to evaluate the lymphoid capacity of cells generated in presence of RA. Due to the low frequency of the HSC-like fraction as seen with RA, we evaluated the CD34^+^ population. By sorting out CD34^+^ cells, generated either with or without DEAB or RA, and subculturing them on OP9DL1 for 3 weeks, we observed the presence of non-myeloid (CD33/CD14^−^) CD7^+^ and CD45RA^+^ cells, similar to multipotent early lymphoid progenitors ([@bib11; @bib12; @bib16]) ([Figure 3](#fig3){ref-type="fig"}C). We observed no significant difference in capacity to differentiate into these cells from hematopoietic progenitors generated with or without DEAB or RA, with a possible explanation due to the beneficial role of RA in T cell differentiation ([@bib3]). Together, these results demonstrate that inhibiting RA signaling with DEAB during the generation of hematopoietic cells from human pluripotent stem cells generates cells with the functional capacity to further differentiate toward the lymphoid and the myeloid lineage.

Retinoic Acid Inhibition Increases the Early Developmental Commitment toward the Hematopoietic Lineage {#sec2.4}
------------------------------------------------------------------------------------------------------

The observation that high-dose RA abrogated blood cell generation ([Figure 1](#fig1){ref-type="fig"}C) suggested that the developmental commitment toward the hematopoietic lineage might have been compromised at the level of a non-hematopoietic upstream precursor. Therefore, we reasoned that, during this process, RA inhibition by DEAB might have early positive effects, allowing more of the initial pluripotent cells to differentiate into hematopoietic mesoderm prior to blood production. Indeed DEAB, only during the initial 8 days of the protocol, established a significant positive effect on the final frequency of the HSC-like fraction that was less than the improvement seen when DEAB was applied throughout the protocol (days 0--16) ([Figure 4](#fig4){ref-type="fig"}A). Furthermore, measuring the recently characterized mesodermal precursor of the definitive hematopoietic lineage characterized by a cell-surface marker phenotype highly expressing CD34 and CD90, while being negative for blood markers CD45 and CD43 ([@bib14; @bib33]), we observed that the frequency of these cells were significantly decreased when RA had been added to the culture, on the other hand, DEAB enhanced the proportion of such precursors ([Figures 4](#fig4){ref-type="fig"}B and [S3](#app2){ref-type="sec"}). While these findings demonstrate that part of the improvements seen with decreased RA signaling on blood generation efficiency is developmentally mediated, it does not identify at what stage in the developmental process that this takes place. To evaluate this, we performed quantitative gene expression analysis for a range of developmental marker genes at multiple defined time points throughout our differentiation protocol. The genes and primers used are detailed in [Table S1](#app2){ref-type="sec"}. By this approach, we identified two separate developmental time points where reduced RA signaling would be important for correct lineage commitment toward final hematopoietic mesoderm. The first time point identified was at day 4 during initial germ layer commitment, where mesoderm, measured by expression of *BRACHYURY*, were decreased by RA and increased by DEAB ([Figures 4](#fig4){ref-type="fig"}C and 4D). The second time point identified was at day 8 during the later posterior/anterior specification of the lateral plate mesoderm (LPM), where posterior LPM is the precursor of hemangiogenic mesoderm and the anterior LPM is the precursor of cardiogenic mesoderm. At this time point, we observed a decrease in cardiogenic mesodermal marker gene *NKX2.5* expression in samples treated with DEAB, indicating that decreased RA signaling can decrease the commitment toward cardiogenic lineage ([Figures 4](#fig4){ref-type="fig"}C and 4D). In agreement with this, we observed a significant decrease in the frequency of spontaneously contracting embryoid bodies later at day 15 in our cultures ([Figure 4](#fig4){ref-type="fig"}E), strongly indicating that low levels of RA signaling reduce the commitment of differentiating mesoderm toward the non-hematopoietic cardiac lineage. In addition we observed upregulated expression of *CD38* in cultures with RA, suggesting a possible differentiation of hematopoietic progenitors into more mature CD38^+^ cells ([Figures 1](#fig1){ref-type="fig"}C and [4](#fig4){ref-type="fig"}D). These findings demonstrate that the positive effects of RA signaling inhibition on the efficiency of hematopoietic progenitors generated from pluripotent stem cells is through the mechanism of increased developmental commitment toward the hematopoietic lineage.

Retinoic Acid Signaling Inhibition Maintains the More Primitive Phenotype of Generated Hematopoietic Progenitors {#sec2.5}
----------------------------------------------------------------------------------------------------------------

Modulation of RA signaling has earlier been described to affect the maintenance and expansion ([@bib4; @bib20; @bib27; @bib28]) of subcultured hematopoietic progenitors in the adult setting. We evaluated if there was any beneficial effect of reduced RA signaling on the generated hematopoietic fraction during an additional extended culture period. We observed that the early hematopoietic population, present at day 16, to a large extent is composed of progenitors with a more immature phenotype (CD38^−^CD90^+^), while prolonged cultures until day 21 display a maturational shift where the more mature cell fraction (CD34^−^CD38^+^) becomes expanded ([Figure 5](#fig5){ref-type="fig"}A), thus indicating a relationship between the hematopoietic fractions similar to the current models of lineage determination in the adult hematopoietic hierarchy ([@bib7]). We then analyzed the relative distribution of the progenitor fraction and HSC-like fraction within the hematopoietic population at days 16 and 21 with or without DEAB treatment. While the DMSO control demonstrated the typical loss of progenitors (CD34^+^) with increased amounts of more mature cells (CD34^−^CD38^+^) ([Figure 5](#fig5){ref-type="fig"}B, left and middle panel), DEAB reduced this transition. Furthermore, the increase in HSC-like frequency was increased for cultures with DEAB that were kept until day 21, relative to 16 days ([Figure 5](#fig5){ref-type="fig"}B, right panel). These findings indicate that reduced RA signaling better maintains the immaturity of the generated hematopoietic progenitor fraction. Taken together, these results demonstrate that RA signaling influences the development of blood through the two mechanisms of developmental commitment and blood progenitor maturation and that decreased RA signaling enables increased generation efficiency of hematopoietic progenitors from human pluripotent stem cells in vitro.

Discussion {#sec3}
==========

In this study, we dissected the role of RA signaling in human hematopoietic development, using a human pluripotent stem cell differentiation system as an in vitro model, to generate hematopoietic progenitors. We have identified multiple stages in development that are influenced by RA signaling, where modulation of RA signaling directs the generation of hematopoietic cells from pluripotent stem cells in vitro. We report that RA decreases blood generation from human pluripotent stem cells. RA signaling inhibition before the onset of hematopoiesis establishes an increase in the final output of cells with an HSC-like phenotype that confirms the role of RA signaling in the early stages of blood generation. qRT-PCR analysis for genes marking specific developmental cell types identified the stages during development where decreased RA signaling increased commitment toward the hematopoietic lineage, including the initial commitment of pluripotent stem cells to mesoderm, and by increased specification toward hemangiogenic mesoderm, while reducing cardiac mesoderm differentiation. The suppressing effect of RA on mesodermal commitment has been described in the murine embryo ([@bib1; @bib22]), and RA has been demonstrated to direct mesoderm toward cardiac tissue (anterior LPM) at the expense of hematopoietic development in *Xenopus* ([@bib6]), zebrafish ([@bib5]), and mouse ([@bib32]), but this is the first time that these functions of RA have been verified in human development. Taken together, these results suggest that high but physiological levels of RA antagonize blood development and that substantially lower amounts of RA signaling relative to other tissues in the developing embryo are required to facilitate blood development. We show that RA accelerates the differentiation of generated hematopoietic progenitors to more mature blood cells, in agreement with findings in the adult human bone marrow where RA scavenging stroma cells is crucial to prevent rapid differentiation of hematopoietic progenitors ([@bib9]). By restricting RA signaling using DEAB, we demonstrate a significant increase in the generation of HSC-like progenitors capable of lymphoid and myeloid differentiation (∼3-fold). In this study, we performed transplantation experiments to assess the capacity of these cells to repopulate immunocompromised mice but found no significant difference in engraftment capacity in progenitors derived from human pluripotent stem cells (data not shown). Our results using DEAB may appear to contradict findings that RA can increase the progenitor output generated from human ESCs ([@bib36]); however, Yu et al. only assessed the effect of RA on the general CD34^+^ progenitors and did not address the action of RA to differentiate and ultimately reduce the numbers of more immature hematopoietic progenitors; indeed, we observed that adding low amounts of RA increased total blood output but at the expense of the HSC-like progenitor fraction (the fraction with the highest lymphoid/myeloid differentiation potential). Our findings indicate that reduced RA signaling preserves the generated progenitor fraction from differentiation into more mature cell types, similar to the finding that DEAB delayed the differentiation of subcultured human cord blood and bone marrow HSCs ([@bib4]). Regarding the role of RA signaling on blood development, a recent study on the cephalochordate Amphioxus (*Branchiostoma lanceolatum*), considered to be one of the most closely related invertebrates to the vertebrate family ([@bib23]), reported that HSC-equivalent Pdvegfr^+^ Scl^+^ cells in the aorta-gonad-mesonephros (AGM) during embryonic development were abrogated when the embryos were treated with RA. This indicates that first, RA, at concentrations above what is naturally found at embryonic sites of hematopoiesis, can be a strong negative regulator of blood development, and second, that the relationship between RA signaling and development toward the hematopoietic lineage is a shared feature across all members of the vertebrate subphylum. Therefore, it is possible that, from an evolutionary perspective, blood development depends on an RA-low environment with controlled low levels of RA being critical during separate stages during this process, a process mimicked in our human model in the presence of DEAB. While our data demonstrate that increasing concentrations of RA abrogate the development of blood, it is important to appreciate that RA signaling is needed in this developmental process, albeit at controlled levels, since full abrogation of RA signaling, as demonstrated in the murine setting ([@bib2; @bib10]), is incompatible with hematopoietic development and the emergence of HSCs at the AGM. In addition, Chanda et al. demonstrate that increases in RA signaling around the time of HSC emergence from hemogenic endothelium increase transplantable HSCs in the murine setting; however, whether any expansion of already-committed HSCs occurred in the culture was not addressed. Our concept that RA is required at low levels during blood development helps to explain the contradicting views on RA in blood development and provides a more unified model for this process. As RA has been shown to have pleiotropic effects on separate hematopoietic cell types ([@bib25]), and by the evidence that signaling through specific receptor elements confers separate responses in different populations ([@bib2; @bib28]), it would be fitting to describe the nature of RA signaling to be context dependent. Identification and manipulation of specific RA receptors in specific cell populations will allow for further understanding and better recapitulation of development toward blood. Taken together, we have provided evidence identifying multiple developmental stages that depend on restricted RA signaling for the efficient differentiation toward blood, and we have shown that RA signaling inhibition can prevent differentiation and loss of more immature blood progenitors generated in vitro. Our findings show the utility of our pluripotent stem cell differentiation system to study human hematopoietic development, modeling human embryonic development, and to determine the effects and functions of RA during this process.

Experimental Procedures {#sec4}
=======================

Pluripotent Stem Cell Culture and Hematopoietic Differentiation {#sec4.1}
---------------------------------------------------------------

The human ESC lines H1 and HUES 3 (obtained from WiCell and Harvard University, respectively, under material transfer agreements) and the iPSC cell line RB9-CB1 (derived from cord blood endothelial cells transduced with tetracycline-inducible lentiviral vectors expressing *OCT4*, *SOX2*, *LIN28*, *KLF4*, and *C-MYC*) ([@bib35]) were used in this study. The lines were karyotypically normal and have previously been demonstrated to be pluripotent by in vivo teratoma assay and PCR. The pluripotent stem cell lines were routinely maintained and differentiated toward blood, as previously described ([@bib35]), with some modifications. The modifications were as follows: prior to embryoid body (EB) formation, colonies of pluripotent stem cells were cultured an additional 24 hr to increase colony density. During the EB-formation stage, the 7-day culture was extended to 8 days with a 1.5-fold increase in media volume. For adherence plating of EBs, a coating of Matrigel was used instead of OP9 stroma. The pluripotent stem-cell-to-blood differentiation medium MesoTotal (Primorigen Biosciences), with and without DEAB, was added 24 hr after EB formation, and fresh media was added every 2 days throughout the differentiation until day 16 or day 21 (extended culture period). DEAB (Sigma), LG1506 (Tocris Bioscience), and RA (Sigma) were resuspended in DMSO and added at specific concentrations to the differentiation media.

Flow Cytometry {#sec4.2}
--------------

Differentiated cells were washed in PBS before being singularized using TrypLE (Thermo Fischer Scientific), passed through a 21G needle, and filtered using 30 μm sterile Cup Filcons (BD Biosciences). Cells were treated with 7AAD to exclude dead cells. Cells were stained using the following anti-human antibodies; fluorescein isothiocyanate (FITC)-conjugated CD45 (eBioscience, 11-0459-42) and CD43 (BD Biosciences, 555475), phycoerythrin-cyanine (PE-Cy7)-conjugated CD34 (BioLegend, 343516), allophycocyanin-conjugated CD38 (BioLegend, 303510), CD33 (BioLegend, 303408), CD14 (BioLegend, 325608) Phycoerythrin (PE)-conjugated CD90 (BioLegend, 328110), CD19 (BioLegend, 302208), CD7 (BD Biosciences, 332774), V450-conjugated CD45RA (BD Biosciences, 560362), PE-Cy5-CD56 (BioLegend, 304608), BV605-CD45RA (BioLegend, 304133), and eFluor450-CD16 (eBioscience, 48-0168-42). Cells were acquired on a FACS Canto II (BD Biosciences) or sorted using a FACS Aria III (BD Biosciences). Analysis was done using FlowJo, version 9.4.10 (BD Biosciences). FACS gates are based on fluorescence minus one (FMO) controls unless stated otherwise.

CFU Assay {#sec4.3}
---------

Single-cell suspensions of harvested differentiation cultures (20,000 cells per well) or, alternatively, sorted blood progenitor cells were plated in 2 ml of MethoCult H4435 (STEMCELL Technologies) in Falcon Tissue Culture six-well plates (Thermo Fisher Scientific). RA and DEAB were not added to the methylcellulose. Cells were incubated for 14 days in a humidified incubator at 37°C with 5% CO~2.~ Colonies were counted by bright-field microscopy.

Lymphoid Differentiation Assay {#sec4.4}
------------------------------

EBs obtained from pluripotent stem cells were differentiated on OP9 ([@bib18]) and OP9-Delta1 (OP9D1) ([@bib14]) stroma monolayer for NK cell and T cell differentiation, respectively, in Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum. To obtain NK cells, EBs were differentiated for 4 weeks in the presence of interleukin-3 (IL-3) (5 ng/ml), IL-7 (5 ng/ml), stem cell factor (SCF) (10 ng/ml), and Flt-3L (10 ng/ml) (all from PeproTech). Wells were scored positive if showing a cluster of more than ten NK cells. To obtain T cells, CD34^+^ hematopoietic progenitors obtained from the differentiating EBs were plated on OP9D1 cells and differentiated for 3 weeks in the presence of Flt-3L (5 ng/ml) and IL-7 (5 ng/ml). SCF (100 ng/ml) was applied only for the initial 5 days. The differentiating cells were collected (vigorous pipetting and filtering through a 40 μm nylon mesh) and re-plated every 7 days on fresh stroma. Fresh media and cytokines were replenished twice every 7 days. At the end of subculture, cells were collected and analyzed by flow cytometry. Cord blood cells, collected after informed consent at the Lund University hospital, were used as positive control and were prepared using Lymphoprep tubes (Axis-Shield), together with CD34^+^ enrichment using the Direct CD34 Progenitor Cell Isolation Kit together with MACS separation columns (both from Miltenyi Biotech).

Quantitative Real-Time PCR {#sec4.5}
--------------------------

RNA was extracted from differentiation cultures with the RNeasy Micro Kit (QIAGEN) according to the manufacturer's specifications. The extracted RNA was transcribed into cDNA using random hexamers, dinucleotide triphosphates (dNTPs), 5× first strand buffer, DTT, RNaseOUT, and SSIII (Thermo Scientific). The qRT-PCR analysis was carried out with SYBR green (Sigma) detection using Platinum Taq polymerase, SYBR green, and Rox reference dye, dNTPs (all from Thermo Scientific), and primers (Sigma) (for primer sequences, see [Table S1](#app2){ref-type="sec"}) on an ABI 7900HT Fast Real Time PCR cycler (Thermo Scientific). Reaction efficiency was calculated for each primer pair with serial dilutions of cDNA template, and melting curve analysis was performed at the end of each reaction for detection of unspecific product amplification. Relative quantification of transcript levels were calculated using ΔC~T~ values normalized to *β-ACTIN*, and the fold change of gene expression was calculated relative to day 0 of differentiation.

Statistical Analysis {#sec4.6}
--------------------

Statistical analysis was performed using an unpaired Student's t test, and the results were considered to be statistically significant at p value \< 0.05. All graphs depict mean ± SEM. The number of biological replicates is indicated by the n value. The graphs and statistical evaluation were done using GraphPad Prism (GraphPad Software).
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![Retinoic Acid Signaling Inhibition Increases the Yield of Hematopoietic Progenitors with an HSC-like Phenotype from Human Pluripotent Stem Cells\
(A) Schematic of pluripotent stem cell differentiation system used to model human hematopoietic development through mesoderm specification and blood commitment. RA inhibitors or RA was present continuously during the 16-day differentiation, except where otherwise stated.\
(B) Representative FACS plots showing the hematopoietic population derived from pluripotent stem cells at day 16 of differentiation. FACS gates show blood (CD45/43^+^), hematopoietic progenitors (CD45/43^+^CD34^+^), and HSC-like immature progenitors (CD45/43^+^CD34^hi^CD38^lo^CD90^+^CD45RA^−^). Gates are based on FMO controls with more stringent CD34^hi^ and CD38^lo^ gating based on cord blood hematopoietic stem and progenitor cell standards. Doublet exclusion and dead cell exclusion were done before applying the gates.\
(C) Frequency (%) of blood subfractions derived from cells treated with DEAB (green) at 10 μM from seven independent experiments (n = 7) (see also [Figures S1](#app2){ref-type="sec"}A and S1B) or RA (orange) (0.01, 0.1, 1.0 μM; n = 3). All values are normalized to the DMSO control (gray) as indicated by the dotted line (100%). X = no events. Bar graphs show change in cell viability as measured by 7AAD for tested conditions.\
(D) mRNA expression level of RA target gene RARβ at day 8 of differentiation (n = 3).\
(E) Frequency of the HSC-like fraction in cells treated with DEAB (n = 7) or an alternative RA signaling inhibitor, LG1506 (1 μM) (blue, n = 3).\
Data represent mean ± SEM. Asterisks indicate significant differences (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001).](gr1){#fig1}

![Retinoic Acid Signaling Inhibition Increases Colony-Forming Hematopoietic Progenitor Numbers\
(A) Micrographs of CFU colony types from iPSC-derived cultures (20,000 cells per sample).\
(B) Cytospin pictures of various hematopoietic cell types collected from colonies and stained with May Grünwald/Giemsa staining, alternatively benzidine.\
(C) Fold change in CFUs from cells treated with DEAB (green) normalized to DMSO control (gray) indicated by the dotted line (100%) from seven independent experiments (n = 7), with pie charts showing the distribution of different colony types.\
(D) Fold change in CFUs after RA treatment, with pie charts showing colony distribution (n = 3).\
(E) Change in maturation markers CD34 and CD38 of the hematopoietic compartment (CD45/43^+^) of cells treated with or without RA. Arrow in FACS plot indicates progression of maturing phenotype.\
Data represent mean ± SEM. Asterisks indicate significant differences (^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001).](gr2){#fig2}

![Retinoic Acid Inhibition Increases the Differentiation Capacity of Hematopoietic Progenitors toward Myeloid and Lymphoid Lineage\
(A) CFU potential of 500 sorted progenitors (CD45/CD43^+^CD34^+^) from DEAB-treated cultures (green) and DMSO control (gray) from four independent experiments (n = 4). CFU potential of progenitors similarly sorted from cord blood (CD45/CD43^+^CD34^+^) is shown in red.\
(B) Lymphoid/myeloid differentiation assay performed on iPSC-derived hematopoietic cells. FACS plots and bar graphs showing non-myeloid (CD33/CD14^-^), CD19^-^, CD56^+^, and CD56^+^CD16^+^ NK fraction from wells seeded with 50 HSC-like cells (CD45/43^+^CD34^hi^CD38^lo^CD90^+^CD45RA^-^) (17 individual wells) cultured on OP9 stroma for 4 weeks. Left bar graph shows the cluster size of the NK fraction. Right bar graph shows the frequency of this population in the viable non-stroma fraction. See also [Figure S2](#app2){ref-type="sec"}.\
(C) FACS plots showing non-myeloid, CD7^+^, CD45RA^+^ multipotent early lymphoid progenitors from 3,500 sorted CD34^+^ cells cultured on OP9DL1 stroma for 3 weeks from one out of two independent experiments (n = 2). FACS plots are gated on the viable non-stroma fraction. Bar graph show the total output of differentiated cells from progenitors generated with DMSO, DEAB, or RA. FACS gates are based on FMO controls.\
Data represent mean ± SEM. Asterisks indicate significant differences (^∗^p \< 0.05).](gr3){#fig3}

![Decreased Retinoic Acid Signaling Improves Early Developmental Commitment toward the Hematopoietic Lineage\
(A) Frequency of the HSC-like fraction in cultures supplemented with DEAB (10 μM), during the first 8 days (n = 3) or during the full 16 days of differentiation (n = 7), as compared to DMSO control. Experiments are independent biological replicates.\
(B) Frequency of the CD43^−^CD34^hi^CD90^hi^ mesoendothelial precursors of the hematopoietic lineage at day 8 for cultures treated with DEAB or RA (n = 4). See also [Figure S3](#app2){ref-type="sec"}.\
(C) Lineage map of the developmental process from pluripotent stem cell to hematopoietic cell. Adjacent wells of cultures treated with or without DEAB were analyzed at days 4, 8, 12, and 16 during differentiation by qRT-PCR for developmental genes including *BRACHYURY* (mesoderm), *MIXL1* (mesoderm), *SOX17* (endoderm), *SOX1* (ectoderm), and *NKX2.5* (cardiac mesoderm).\
(D) Expression of developmental marker genes *BRACHYURY*, *NKX2.5*, and *CD38* for cultures treated with DEAB (n = 3) or RA (n = 2) as compared to DMSO control.\
(E) Frequency (%) of beating colonies at day 15 during differentiation in the presence of DEAB compared to DMSO control (n = 2).\
Data represent mean ± SEM. Asterisks indicate significant differences (^∗^p \< 0.05, ^∗∗∗∗^p \< 0.0001).](gr4){#fig4}

![Decreased Retinoic Acid Signaling Maintains the Primitiveness of Generated Hematopoietic Progenitors\
(A) Representative FACS profiles of cells harvested at day 16 and after extended culture period at day 21. Cells were treated with or without DEAB at 10 μM during the whole culture period.\
(B) Graphs showing fold changes in maturation of the hematopoietic population (CD45/43^+^) observed between day 16 and day 21 for cells treated with DEAB or DMSO from three independent experiments (n = 3).\
Data represent mean ± SEM. Asterisks indicate significant differences (^∗^p \< 0.05).](gr5){#fig5}
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